礼来公司报告阿尔茨海默病研究中ARIA-E发生率降低
印第安纳波利斯 - 礼来公司(NYSE: LLY)公布了其最新的3b期研究结果,显示早期症状性阿尔茨海默病患者中与淀粉样蛋白相关的成像异常伴水肿/渗出(ARIA-E)的发生率有所降低。这项名为TRAILBLAZER-ALZ ...
MedPage Today on MSN1 天
Brain Edema Risk May Be Lower With Modified Donanemab Dosing
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new ...
Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic ...
Eli Lilly and Company (NYSE: LLY) today announced positive results from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a ...
Donanemab：英国获批上市 多国在进程中
【10 月 26 日，英国药品和医疗产品监管局授予药物 donanemab ...
Monthly Prescribing Reference7 小时
Study Shows Modified Donanemab Titration Regimen Cuts Risk of ARIA-E
Modified titration was associated with a 41% lower relative risk of ARIA-E than the standard dosing regimen. Topline results were announced from a phase 3b trial evaluating various dosing regimens of ...
财联社 on MSN6 天
英国批准礼来阿尔茨海默病新药 但药价“太贵”无法广泛使用
礼来并没有透露donanemab在英国的具体售价，但英国最权威的药物和医疗技术评估机构NICE认为这种药物过于昂贵，无法广泛使用，这表明在获得该国药品监管机构的批准后，患者不太可能广泛获得这种药物。
礼来(LLY.US)旗下阿尔茨海默病药物Donanemab遭英国医保监管机构拒绝
智通财经APP获悉，礼来(LLY.US)旗下阿尔茨海默病药物Donanemab将不会提供给使用英国国家医疗服务体系(NHS)的患者，因为药品成本监管机构认为该药物的益处太小，不足以证明其价格合理。据悉，负责决定是否向英国政府资助的NHS患者提供药物的 ...
Eli Lilly says Donanemab redudced ARIA-E in early Alzheimer’s patients
Eli Lilly (LLY) announced “positive results” from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related ...
News Medical on MSN3 天
MHRA greenlights donanemab for early stage Alzheimer’s disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the ...
Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS
Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS - Donanemab and another new drug for ...
腾讯网3 天
礼来阿尔茨海默病药物Kisunla在英国获批上市
10月26日，据礼来消息，英国药品和医疗产品监管局（MHRA）已授予其药物donanemab上市许可。Donanemab（商品名：Kisunla）是一种用于静脉输注的药物，每四周注射一次，在英国获批用于治疗符合条件的轻度认知障碍和轻度阿尔茨海默病（AD）的成人患者。此前，donanemab已于美国、阿联酋、日本和卡塔尔获得上市许可。在中国，d ...